Fig. 5: Mitigating interaction between BETi and bevacizumab in ECs.
From: Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy

a Characteristics of VEGFA-independent (EGM-2MV) and VEGFA-dependent (ESRM and ESFM) culture conditions. FBS, fetal bovine serum; HS, human serum. b, c Relative cell response to bevacizumab in EGM-2MV plus DMSO or JQ1 during days 0–9 (b) or on day 9 (c): JQ1 did not change EC response to bevacizumab under VEGFA-independent conditions. d, e Relative cell response to bevacizumab in ESFM or ESRM plus DMSO or BETi during days 0–9 (d) or on day 9 (e): BETi reversed EC sensitivity to bevacizumab under VEGFA-dependent conditions. f, g Relative cell response to BETi in ESFM or ESRM plus palivizumab or bevacizumab during days 0–9 (f) or on day 9 (g): bevacizumab attenuated survival- and/or proliferation-inhibiting effect(s) of BETi under VEGFA-dependent conditions. A ratio of 1 (black dotted line) indicates no effect on survival and/or proliferation of ECs. Error bars represent ± SEM (n = 2 independent experiments). *P value < 0.05; **P value < 0.01; ***P value < 0.001; ****P value < 0.0001; ns, not significant (two-tailed unpaired t test).